KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer

Future Oncology - Tập 15 Số 9 - Trang 943-952 - 2019
Yung‐Jue Bang1,2, Eric Van Cutsem3, Charles S. Fuchs4, Atsushi Ohtsu5, Josep Tabernero6, David H. Ilson7, Woo Jin Hyung8, Vivian E. Strong9, Thorsten Oliver Goetze10, Takaki Yoshikawa11, Laura H. Tang9, Peggy Hwang12, Nancy R. Webb12, David E. Adelberg12, Kohei Shitara5
1Fax: +82 2 762 9662
2Seoul National University College of Medicine, 101 Daehak-ro, Ihwa-Dong, Seoul, Republic of Korea
3University Hospitals Gasthuisberg Leuven & KU Leuven, 49 Herestraat, Leuven3001, Belgium
4Yale Cancer Center and Smilow Cancer Hospital, 333 Cedar Street, New Haven, CT 06510, USA
5National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan
6Vall d’Hebron University Hospital & Institute of Oncology (VHIO), Vall d’Hebron 119–129, 08035 Universitat Autònoma de Barcelona, Barcelona, Spain
7Memorial Sloan Kettering Cancer Center, 300 East 66th Street, BAIC 1031, New York, NY 10065, USA
8Yonsei Cancer Hospital, Yonsei University Health System, 50-1 Yonsei-Ro Seodaemun-gu, Seoul 03722, Republic of Korea
9Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA
10Institute of Clinical Cancer Research, UCT University Cancer Center Frankfurt, Steinbacher Hohl 2-26, Frankfurt 60488, Germany
11National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
12Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ07033, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.3322/caac.21262

10.1002/ijc.29210

10.1016/S0140-6736(16)30354-3

10.1093/annonc/mdw350

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN guidelines): gastric cancer (Version 2.2018). May 22 2018. www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.

10.1007/s10120-016-0622-4

Li Z , ShanF, WangYet al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PLoS ONE13(1), e0189294 (2018).

10.1002/jso.24517

10.1200/JCO.2010.33.0597

10.1200/JCO.2009.26.6114

10.1056/NEJMoa055531

10.1093/annonc/mdx440.019

10.1056/NEJMoa072252

10.1016/S0140-6736(11)61873-4

Howlader N NooneAM KrapchoMet al. SEER Cancer Statistics Review 1975–2014. National Cancer Institute MD USA. https://seer.cancer.gov/csr/1975_2014/.

10.1111/j.1600-065X.2010.00923.x

10.1038/nrc3239

10.1007/s10147-014-0701-7

10.1016/j.yexmp.2014.03.005

10.18632/oncotarget.8169

10.1371/journal.pone.0182692

10.1007/s10120-015-0519-7

Merck Sharp & Dohme Corp . KEYTRUDA® (pembrolizumab) injection for intravenous use. Whitehouse Station NJ USA (2017).

OPDIVO (nivolumab) injection for intravenous use [prescribing information]. Bristol-Myers Squibb NJ USA (2018).

10.1016/S0140-6736(17)31827-5

10.1016/S1470-2045(16)00175-3

10.1001/jamaoncol.2018.0013

10.1016/S0140-6736(18)31257-1

10.1093/annonc/mdx440.020

10.1158/2159-8290.CD-16-0577

10.1200/JCO.2017.35.15_suppl.506

10.1200/JCO.2017.35.15_suppl.556

10.1200/JCO.2017.35.15_suppl.6012

Merck’s KEYTRUDA® (pembrolizumab) significantly improved recurrence-free survival compared to placebo as adjuvant therapy in patients with stage 3 resected high-risk melanoma (EORTC1325/KEYNOTE-054) [press release]. Business Wire NJ USA (2018).

10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C

Thông tin
Thông tin xuất bản

Future Oncology

Tập 15 Số 9

943-952

Thông tin tác giả